Bicycle Therapeutics plc (BCYC)

Market Cap	539.09M
Revenue (ttm)	35.28M
Net Income (ttm)	-169.03M
Shares Out	69.20M
EPS (ttm)	-2.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	649,748
Open	7.28
Previous Close	7.07
Day's Range	6.97 - 8.00
52-Week Range	6.10 - 28.67
Beta	1.40
Analysts	Buy
Price Target	29.14 (+274.07%)
Earnings Date	May 1, 2025

About BCYC

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 23, 2019
• Employees: 305
• Stock Exchange: NASDAQ
• Ticker Symbol: BCYC
• Website: https://www.bicycletherapeutics.com

Financial Performance

In 2024, Bicycle Therapeutics's revenue was $35.28 million, an increase of 30.76% compared to the previous year's $26.98 million. Losses were -$169.03 million, -6.44% less than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for BCYC stock is "Buy." The 12-month stock price forecast is $29.14, which is an increase of 274.07% from the latest price.

Price Target

$29.14

(274.07% upside)

Analyst Consensus: Buy